# EDGAR Filing Document

**Accession Number:** 0001326190
**File Stem:** 0000000000-25-008327
**Filing Date:** 2025-8
**Character Count:** 3592
**Document Hash:** bb451b0b6135bf805417631f77b257cc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-008327.hdr.sgml**: 20250917

**ACCESSION NUMBER**: 0000000000-25-008327

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250808

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Altimmune, Inc.
- **CENTRAL INDEX KEY:** 0001326190
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 202726770
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-32587

**BUSINESS ADDRESS:**
- **STREET 1:** 910 CLOPPER ROAD
- **STREET 2:** SUITE 201S
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20878
- **BUSINESS PHONE:** 2406541450

**MAIL ADDRESS:**
- **STREET 1:** 910 CLOPPER ROAD
- **STREET 2:** SUITE 201S
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20878

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PHARMATHENE, INC
- **DATE OF NAME CHANGE:** 20071016

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HEALTHCARE ACQUISITION CORP
- **DATE OF NAME CHANGE:** 20050505
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001326190-25-000015

## Text-Extract

```

                                                            August 8, 2025

Gregory Weaver
Chief Financial Officer
Altimmune, Inc.
910 Clopper Road, Suite 201S
Gaithersburg, MD 20878

       Re: Altimmune, Inc.
           Form 10-K for the Fiscal Year Ended December 31, 2024
           Form 10-Q for the Quarterly Period Ended March 31, 2025
           File No. 001-32587
Dear Gregory Weaver:

       We have limited our review of your filing to the financial statements
and related
disclosures and have the following comment.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe
our comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this letter, we may have additional
comments.

Form 10-Q for the Quarterly Period Ended March 31, 2025
Management's Discussion and Analysis of Financial Condition and Results of
Operations,
page 13
Results of Operations, page 14

1.     We note you have not broken out your research and development (R&D)
expenses by
       product or category, unlike in the December 31, 2024 Form 10-K and the
Forms 10-Q
       of 2024. Given R&D continues to account for most of your operating
expenses and
       the expanded indications for pemvidutide, please provide revised
disclosure to be
       included in future filings to quantify your direct R&D by product and
indication for
       each period presented. As part of your response, please provide what
this disclosure
       would have looked like had it been included in your March 31, 2025 Form
10-Q.
        In closing, we remind you that the company and its management are
responsible for
the accuracy and adequacy of their disclosures, notwithstanding any review,
comments,
action or absence of action by the staff.
 August 8, 2025
Page 2

       Please contact Jenn Do at 202-551-3743 or Vanessa Robertson at
202-551-3649 with
any questions.

                                                        Sincerely,

                                                        Division of Corporation
Finance
                                                        Office of Life Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._